期刊文献+

大黄素甲醚改善小鼠非酒精性脂肪性肝病的研究

The improvement provided by physcion on non-alcoholic fatty liver disease in mice
原文传递
导出
摘要 大黄素甲醚(physcion,PHY)是一种来源于大黄等中药的蒽醌类化合物。本实验旨在探究PHY对非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)的改善作用及其机制。采用蛋氨酸胆碱缺乏饲料(methionine-and choline-deficient diet,MCD)喂养6周诱导小鼠NAFLD疾病模型(本实验获得上海中医药大学实验动物伦理委员会批准,批准号:PZSHUTCM190705019)。结果显示,PHY(5和20 mg·kg^(-1))能改善MCD诱导NAFLD小鼠的肝损伤,减轻肝脏脂肪累积,降低升高的NAFLD活动性评分(NAFLD activity score,NAS)。Western blot及酶活力实验结果提示,PHY能提升肝脏及L-02细胞中肉毒碱棕榈酰基转移酶1A(carnitine palmitoyltransferase 1A,CPT1A)蛋白表达及酶活力,但real-time PCR结果显示PHY不影响Cpt1a mRNA表达。免疫荧光结果提示,PHY(10和25μmol·L^(-1))能缓解游离脂肪酸(non-esterified fatty acids,NEFA)诱导的人正常肝L-02细胞中的线粒体损伤。Seahorse实验结果提示,PHY给药后能提升L-02细胞内线粒体基础呼吸能力、最大呼吸能力、ATP合成和储备呼吸能力,但不影响线粒体质子漏。以上研究表明,PHY可能通过改善线粒体功能,促进脂肪酸β氧化,减少肝脏中脂肪的堆积,发挥改善NAFLD的药效。 Physcion(PHY)is an anthraquinone compound derived from traditional Chinese medicine such as Rhei Radix et Rhizoma.The aim of this study is to investigate the improvement of PHY on non-alcoholic fatty liver disease(NAFLD)and its underlying mechanism.NAFLD was induced in mice by feeding with the methionine-and choline-deficient diet(MCD)for 6 weeks.This experiment was approved by the Experimental Animal Ethics Committee of Shanghai University of Traditional Chinese Medicine(approval number:PZSHUTCM190705019).The results displayed that PHY(5 and 20 mg·kg^(-1))reversed liver damage,reduced hepatic lipid accumulation and decreased the elevated NAFLD activity score(NAS)in MCD-fed NAFLD mice.Results from Western blot and enzyme activity demonstrated that PHY could enhance the protein expression and enzyme activity of carnitine palmitoyltransferase 1A(CPT1A)in the liver and L-02 cells,but it did not affect Cpt1a mRNA expression.Immunofluorescence results indicated that PHY(10 and 25μmol·L^(-1))could reduce the mitochondrial injury induced by non-esterified fatty acids(NEFA)in L-02 cells.Results from seahorse assay showed that PHY could enhance mitochondrial basic respiration,maximal respiration,ATP synthesis and reserve respiration in L-02 cells treated with NEFA,but had no effect on mitochondrial proton leakage.In summary,PHY reversed mitochondrial damage and enhanced fatty acidβ-oxidation,thereby reducing hepatic steatosis and improving NAFLD.
作者 张进宇 张少波 徐红 欧阳豪 季莉莉 ZHANG Jin-yu;ZHANG Shao-bo;XU Hong;OUYANG Hao;JI Li-li(The MOE Key Laboratory for Standardization of Chinese Medicines,the SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines,Shanghai Key Laboratory of Compound Chinese Medicines,Institute of Chinese Materia Medica,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Department of Hepatology,Yueyang Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China)
出处 《药学学报》 CAS CSCD 北大核心 2024年第4期939-947,共9页 Acta Pharmaceutica Sinica
基金 国家自然科学基金资助项目(82273994,82173958).
关键词 大黄素甲醚 非酒精性脂肪性肝病 肉毒碱棕榈酰基转移酶1A β氧化 线粒体损伤 physcion non-alcoholic fatty liver disease carnitine palmitoyltransferase 1A β-oxidation mitochondrial damage
  • 引文网络
  • 相关文献

参考文献4

二级参考文献57

  • 1Nobili V, Alkhouri N, Alisi A, Della Corte C, Fitzpatrick E, RaponiM, Dhawan A. Nonalcoholic fatty liver disease: a challenge for pediatricians. JAMA Pediatr 2015; 169: 170-176 [PMID: 25506780DOI: 10.1001/jamapediatrics.2014.2702].
  • 2Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, ContrerasM, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liverdisease and nonalcoholic steatohepatitis among a largely middleagedpopulation utilizing ultrasound and liver biopsy: a prospectivestudy. Gastroenterology 2011; 140: 124-131 [PMID: 20858492DOI: 10.1053/j.gastro.2010.09.038].
  • 3Anstee QM, Targher G, Day CP. Progression of NAFLD todiabetes mellitus, cardiovascular disease or cirrhosis. Nat RevGastroenterol Hepatol 2013; 10: 330-344 [PMID: 23507799 DOI:10.1038/nrgastro.2013.41].
  • 4Vernon G, Baranova A, Younossi ZM. Systematic review: theepidemiology and natural history of non-alcoholic fatty liver diseaseand non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther2011; 34: 274-285 [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x].
  • 5Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histologyin obese patients undergoing bariatric surgery. J Hepatol 2006; 45:600-606 [PMID: 16899321].
  • 6Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E,Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and itsconnection with insulin resistance, dyslipidemia, atherosclerosisand coronary heart disease. Nutrients 2013; 5: 1544-1560 [PMID:23666091 DOI: 10.3390/nu5051544].
  • 7Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA,Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the secondleading etiology of liver disease among adults awaiting livertransplantation in the United States. Gastroenterology 2015; 148:547-555 [PMID: 25461851 DOI: 10.1053/j.gastro.2014.11.039].
  • 8Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, HuiJM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, WeltmanM, George J. NASH and insulin resistance: Insulin hypersecretionand specific association with the insulin resistance syndrome.Hepatology 2002; 35: 373-379 [PMID: 11826411].
  • 9Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A,Erbel R, Blankstein R, Feldman T, Al-Mallah MH, Santos RD,Budoff MJ, Nasir K. A systematic review: burden and severity ofsubclinical cardiovascular disease among those with nonalcoholicfatty liver; should we care- Atherosclerosis 2013; 230: 258-267[PMID: 24075754 DOI: 10.1016/j.atherosclerosis.2013.07.052].
  • 10Than NN, Newsome PN. A concise review of non-alcoholicfatty liver disease. Atherosclerosis 2015; 239: 192-202 [PMID:25617860 DOI: 10.1016/j.atherosclerosis.2015.01.001].

共引文献339

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部